Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function

Simple item page
dc.contributor.authorAlbayrak, Sinan
dc.contributor.authorOrdu, Serkan
dc.contributor.authorÖzhan, Hakan
dc.contributor.authorYazıcı, Mehmet
dc.contributor.authorAydın, Mesut
dc.contributor.authorAlemdar, Recai
dc.contributor.authorKaya, Ahmet
dc.date.accessioned2020-05-01T09:11:44Z
dc.date.available2020-05-01T09:11:44Z
dc.date.issued2009
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionWOS: 000269389400004en_US
dc.descriptionPubMed: 19521888en_US
dc.description.abstractSerum cystatin C concentration is an alternative measure of kidney function that is less affected by age, sex or muscle mass, and is a more sensitive indicator of early renal dysfunction than creatinine-based estimations of glomerular filtration rate. Cardiovascular sequela increases progressively with the increase in left ventricular mass. Our goal was to evaluate the effect of olmesartan medoxomil on cystatin C levels and left ventricular hypertrophy (LVH) in patients with hypertension. Forty-four newly diagnosed hypertensive patients (27 women and 17 men) were recruited in the study. Olmesartan medoxomil (20 mg/day) was started and the patients were followed up for 6 months. Baseline echocardiographic findings (i.e. left ventricular mass index), serum creatinine, urine albumin/creatinine ratio (ACR) and serum cystatin C levels were compared with the levels of these variables measured at the end of 6-month follow-up period. After 6 months of treatment with olmesartan medoxomil, there was a significant reduction in systolic and diastolic blood pressure (p < 0.001) and in urine ACR (p = 0.04). Mean serum cystatin C levels decreased from 1.61 +/- 0.24 mg/l to 1.31 +/- 0.29 mg/l (p < 0.001). Olmesartan medoxomil treatment also reduced left ventricular mass index (p < 0.001) and LVH (p < 0.001). Our findings indicate that olmesartan medoxomil decreases serum cystatin C levels, urine ACR and reduces LVH in patients with hypertension. To our knowledge, this study is the first to show that olmesartan medoxomil decreases serum cystatin C levels, indicating that in patients with essential hypertension it may counteract end organ damage.en_US
dc.identifier.doi10.1080/08037050903047236en_US
dc.identifier.endpage191en_US
dc.identifier.issn1651-1999
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage187en_US
dc.identifier.urihttps://doi.org/10.1080/08037050903047236
dc.identifier.urihttps://hdl.handle.net/20.500.12684/5743
dc.identifier.volume18en_US
dc.identifier.wosWOS:000269389400004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofBlood Pressureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCystatin Cen_US
dc.subjecthypertensionen_US
dc.subjectleft ventricular hypertrophyen_US
dc.subjectmicroalbuminuriaen_US
dc.titleEffect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic functionen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
5743.pdf
Size:
139.21 KB
Format:
Adobe Portable Document Format
Description:
Tam Metin / Full Text
Download

Collections

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize